Current Research Studies

EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

EPIK P4

Condition(s): Other
Phase: II
Clinicaltrials.gov ID: NCT06997588

What is the goal of the study?

Study assessing the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Juliana Bonilla-Velez
Study Team Member: Thao Amy Nguyen, [email protected]